Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Somnomed Limited ( (AU:SOM) ).
SomnoMed Limited announced that the Australian Stock Exchange has advised the company that it is no longer required to submit quarterly activity and cashflow reports. As a result, SomnoMed will transition to half-year and full-year reporting after releasing its Q1 FY26 update on 30 October 2025. This change is expected to streamline the company’s reporting process and may impact how stakeholders track the company’s financial performance.
The most recent analyst rating on (AU:SOM) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
More about Somnomed Limited
SomnoMed is a public company that specializes in providing treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. The company is known for its clinically proven medical oral appliance therapy, SomnoDent, which has been used by over 1 million patients in more than 20 countries.
Average Trading Volume: 365,392
Technical Sentiment Signal: Buy
Current Market Cap: A$187.6M
See more insights into SOM stock on TipRanks’ Stock Analysis page.